Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Captopril and immune regulation.

J F Delfraissy, P Galanaud, J F Balavoine

    Kidney International
    |June 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [French research organization on emerging infectious diseases: From REACTing to ANRS emerging infectious diseases].

    Bulletin de l'Academie nationale de medecine·2023
    Same author

    Weight-for-height Z-score improves in half of undernourished children hospitalized in surgical wards.

    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2020
    Same author

    The control of diabetes and other Non-communicable Diseases is an urgent health priority in Africa: Grenoble declaration.

    Medecine et sante tropicales·2019
    Same author

    One-year results of the SCANDIV randomized clinical trial of laparoscopic lavage versus primary resection for acute perforated diverticulitis.

    The British journal of surgery·2017
    Same author

    ANTI-IL-2 Receptor Antibody Treatment for Lymphoproliferative Disease: Transient Response in A Case of Ki-1+ Anaplastic Large Cell Lymphoma.

    Leukemia & lymphoma·2016
    Same author

    Progressive contraction of the latent HIV reservoir around a core of less-differentiated CD4⁺ memory T Cells.

    Nature communications·2014
    Same journal

    KDIGO Life Cycle of Guideline Development Series Part 6: Bridging the Gap between Guidelines and Clinical Practice: The KDIGO Approach to Global Implementation and Education in Nephrology.

    Kidney international·2026
    Same journal

    KDIGO Life Cycle of Guideline Development Series Part 5: Guideline updates and a living model for the future.

    Kidney international·2026
    Same journal

    Crystal-Storing Histiocytosis Causing Severe AKI.

    Kidney international·2026
    Same journal

    Peritoneal dialysis in a patient with extensive burn scarring.

    Kidney international·2026
    Same journal

    COPA syndrome unmasked by anti-neutrophil cytoplasmic antibody-positive immune-complex nephritis.

    Kidney international·2026
    Same journal

    Monitoring anti-nephrin antibodies in the management of recurrent diffuse podocytopathy.

    Kidney international·2026
    See all related articles

    Captopril, an ACE inhibitor, suppresses human B cell antibody production by activating a suppressor circuit involving monocytes and T cells. This immune modulation occurs both in vitro and in vivo.

    Area of Science:

    • Immunology
    • Pharmacology

    Background:

    • The immune system's regulation is crucial for preventing autoimmune diseases and maintaining tolerance.
    • Angiotensin-Converting Enzyme (ACE) inhibitors, like captopril, are widely used for hypertension.
    • The immunomodulatory effects of ACE inhibitors are not fully understood.

    Purpose of the Study:

    • To investigate the in vitro and in vivo effects of captopril on the human primary antibody response.
    • To elucidate the cellular mechanisms underlying captopril-induced immune suppression.

    Main Methods:

    • In vitro culture of human peripheral blood mononuclear cells (PBM).
    • Assessment of specific anti-trinitrophenyl (TNP) antibody response.
    • Cell transfer experiments involving adherent and nonadherent PBM fractions.

    Related Experiment Videos

  • In vivo studies after oral captopril administration.

    • Main Results:

    • Captopril (2.5-5 µg/ml) suppressed the anti-TNP antibody response of unfractionated PBM by 50%.
    • Suppression was dependent on adherent cells and radiosensitive T cells, involving monocytes and T8 suppressor lymphocytes.
    • Induced suppression could be transferred by T effector cells.
    • In vivo oral captopril induced suppressor activity in adherent cells.

    Conclusions:

    • Captopril interferes with immune regulation by inducing a suppressor circuit.
    • This circuit involves monocytes and T8 suppressor effector lymphocytes.
    • Captopril exhibits immunomodulatory properties affecting B cell antibody production.